STAT+: Novartis to buy Chinook Therapeutics, developer of kidney disease therapies, in $3.2 billion deal
Novartis said it would purchase Chinook Therapeutics, picking up two drugs for a chronic kidney disease.
LONDON — Novartis said on Monday it would purchase Chinook Therapeutics for $3.2 billion upfront, picking up two drugs for a chronic kidney disease that are in late-stage clinical trials.
The transaction values Seattle-based Chinook at $40 a share, compared to Friday’s closing price of under $24. The agreement includes another $300 million if certain regulatory milestones are reached.
The acquisition, which adds to a steady return for biopharma deals this year, is expected to close in the second half of 2023.
What's Your Reaction?
